$IGC News
Last published 4h ago
- 4h agoANVSACIUIGCAIFFPRISM MarketView Highlights Four Small Caps Working on Alzheimer’s Disease for National Alzheimer’s Disease Awareness MonthGlobeNewswireFeature reviews this week’s CTAD 2026 readouts and where four small-cap companies stand in pills, immunotherapy, agitation treatment and brain testing
- 1d agoIGCIGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's DementiaACCESS NewswireIGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company"), a clinical-stage biotechnology company developing investigational therapies for Alzheimer's disease, today announced the completion of the six-week treatment phase of CALMA for all its 170 participants. The final participant has completed dosing, and all required treatment-period visits and assessments are complete. The trial ra ...
- 1w agoIGCAlzheimer's Phase 2 Trial in AgitationACCESS NewswireIGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company"), a clinical-stage biotechnology company developing investigational therapies and AI-enabled tools for Alzheimer's disease, today reported financial results and business updates for the third quarter ended September 30, 2026. "CALMA enrolled is complete." said Ram Mukunda, Chief Executive Officer of IGC Pharma. "Once the last part ...
- 2w agoIGCIGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout NearsACCESS NewswireCanada grants patent on IGC-AD1, an investigational oral therapy for agitation in Alzheimer's disease. Agitation is one of the hardest symptoms for families to manage. POTOMAC, MD / ACCESS Newswire / November
- 1mo agoIGCIGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial DeploymentACCESS NewswirePOTOMAC, MD / ACCESS Newswire / October 13, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and
- 1mo agoIGCIGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026ACCESS NewswirePOTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset,
- 3mo agoIGCIGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment ClosureACCESS NewswirePhase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology
- 3mo agoIGCIGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline ReadoutACCESS NewswirePOTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today
- 3mo agoIGCIGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short CampaignACCESS NewswirePOTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today
- 4mo agoIGCIGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative WorkflowACCESS NewswireSeven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development POTOMAC, MD /
- 4mo agoIGCIGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the CompanyACCESS NewswireSenior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7,
- 4mo agoIGCIGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative WorkflowACCESS NewswirePatent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London POTOMAC, MD / ACCESS
- 5mo agoIGCIGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline AnalysisACCESS NewswireCompany Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / June 11, 2026 / IGC
- 5mo agoIGCAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 CatalystsACCESS NewswirePOTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant
- 5mo agoIGCIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline AnalysisACCESS NewswireApproximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma, Inc.
- 6mo agoIGCIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% EnrollmentACCESS Newswire- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing therapeutics and
- 6mo agoIGCIGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau ConferenceACCESS NewswireResearch highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026 / IGC Pharma, Inc.
- 6mo agoIGCIGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment PhaseACCESS NewswireOutreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. , a
- 7mo agoIGCIGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward CompletionACCESS NewswireBehavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. ("IGC" or the
- 7mo agoIGCIGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in DementiaACCESS NewswireAuthorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc.
- 7mo agoIGCIGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data ReadoutACCESS NewswirePOTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating
- 7mo agoIGCAscendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming CatalystsACCESS NewswirePOTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating
- 7mo agoIGCIGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's DiseaseACCESS NewswirePOTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the
- 7mo agoIGCIGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor AwarenessACCESS NewswirePOTOMAC, MD / ACCESS Newswire / March 30, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced a strategic
- 8mo agoIGCIGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025ACCESS Newswire- Strategic Pivot to Pure-Play Biotech -POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing therapeutics for
- 8mo agoIGCIGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026ACCESS NewswirePOTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will
- 8mo agoIGCIGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's ResearchACCESS NewswirePOTOMAC, MD / ACCESS Newswire / February 26, 2026 / IGC Pharma, Inc. , a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the filing
- 8mo agoIGCIGC Pharma Notes Updated Research Coverage from Ascendiant Capital MarketsACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / February 24, 2026 / IGC Pharma, Inc. , today announced that Ascendiant Capital Markets has issued an updated equity research report covering the
- 8mo agoIGCIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA TrialACCESS Newswire- Practice integrated neurology network expands enrollment capacity -POTOMAC, MARYLAND / ACCESS Newswire / February 23, 2026 / IGC Pharma, Inc. , today announced the addition of
- 9mo agoIGCIGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment AdvancesACCESS NewswirePOTOMAC, MD / ACCESS Newswire / February 17, 2026 / IGC Pharma, Inc. , today announced that the Canadian Intellectual Property Office has issued a Notice of Allowance covering
- 9mo agoIGCIGC Pharma to Participate in Fireside Chat With Ascendiant Capital MarketsACCESS NewswirePOTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. , today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by
- 9mo agoIGCIGC Pharma Announces Equity Research Update by Alliance Global PartnersACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / February 10, 2026 / IGC Pharma, Inc. , today announced that Alliance Global Partners has published an updated equity research report
- 9mo agoIGCIGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research CenterACCESS Newswire- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst -POTOMAC, MARYLAND / ACCESS Newswire / February 9, 2026 / IGC Pharma, Inc.
- 9mo agoIGCIGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's AgitationACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. , today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical
- 11mo agoIGCIGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory MomentumACCESS Newswire- New Patent Expands IGC Pharma's Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer's Disease -POTOMAC, MD / ACCESS Newswire / December 19, 2025 / IGC Pharma, Inc. , a
- 11mo agoIGCIGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid MedicinesACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / December 15, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging Artificial Intelligence to develop innovative
- 11mo agoIGCIGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."ACCESS NewswirePOTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging Artificial Intelligence to develop
- 11mo agoIGCIGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation TrialACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / December 9, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging Artificial Intelligence to develop
- 11mo agoIGCIGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's DiseaseACCESS NewswireNew Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma's Leadership in Alzheimer's Innovation POTOMAC, MD / ACCESS Newswire / December 2, 2025 / IGC Pharma, Inc. ("IGC" or
- 11mo agoIGCIGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging TrendsACCESS NewswirePOTOMAC, MD / ACCESS Newswire / November 25, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging AI to develop
- 1y agoIGCIGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes CapitalACCESS NewswireCompany Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging Recognition for AI Leadership POTOMAC, MARYLAND / ACCESS Newswire / November 17, 2025 / IGC Pharma, Inc.
- 1y agoIGCUSPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System DisordersACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / November 13, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging Artificial
- 1y agoIGCIGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025ACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / November 10, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging AI to develop
- 1y agoIGCIGC Pharma Expands AI-Powered Drug Discovery In-Silico PipelineACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging AI to develop
- 1y agoIGCIGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"ACCESS NewswirePOTOMAC, MD / ACCESS Newswire / October 22, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging AI to develop
- 1y agoIGCIGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral NeurosciencesACCESS NewswirePOTOMAC, MD, 1734 / ACCESS Newswire / October 14, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging AI to develop
- 1y agoIGCIGC Pharma Announces Results of 2025 Annual Meeting of StockholdersACCESS NewswirePOTOMAC, MARYLAND / ACCESS Newswire / October 10, 2025 / IGC Pharma, Inc. , a clinical-stage biotechnology company leveraging AI to develop
- 1y agoIGCIGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's DiseaseACCESS NewswireIGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation , Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MD, 1734 / ACCESS Newswire / October 7, 2025 / IGC Pharma, Inc.
- 1y agoIGCIGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's PathologyACCESS NewswirePOTOMAC, MD / ACCESS Newswire / September 24, 2025 / IGC Pharma, Inc. today announced preclinical findings on TGR-63, the Company's investigational small-molecule candidate for Alzheimer's disease. The data
- 1y agoIGCIGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation TrialACCESS NewswirePOTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. , a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has reached a key enrollment